Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized synthetic long peptide vaccine in persistent TNBC
NCT02427581Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2015
- Primary completion
- Dec 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label, single-arm trial of NeoSLP in triple-negative breast cancer (TNBC), sponsored by Washington University School of Medicine. Primary endpoint: Safety of the vaccine regimen at 1 year. Planned start Sep 2015; status: withdrawn.
02
Drugs
NeoSLP
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02427581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02427581.